Skip to content

Current ratio at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
4.1×-5.6×
ALN
Alnylam PharmaceuticalsALNY
3.1×+0.1×
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
18×+2.3×
Beam Therapeutics logo
Beam TherapeuticsBEAM
17×+8.2×
Iovance Biotherapeutics, Inc. logo
Iovance Biotherapeutics, Inc.IOVA
3.6×-0.6×
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
15.1×-4.3×

Other financials

Income statement

See full
Revenue$15.0M-9.5%
Operating income-$100.5M+16.8%
Net income-$96.2M+15.8%
EPS (diluted)-$0.81+26.4%

Balance sheet

See full
Cash & equivalents$134.7M+6.2%
Total debt$80.5M-32.5%
Total equity$620.9M-20.4%
Total assets$758.8M-23.1%

Cash flow

See full
Operating cash flow-$117.3M+21.2%
CapEx$79.0K-89.3%
Free cash flow-$117.4M+21.5%

Valuation

See full
Market cap$2.13B+106%
Enterprise value$2.08B+100%
P/S32.2×+9.5×

Profitability

See full
Operating margin-636.6%-202pp
Net margin-597%-194pp
FCF margin-550.2%-140pp

Returns & leverage

See full
Return on equity-56.3%-1.5pp
Debt / equity0.1×0.0×

Where this comes from

Calculated from Intellia Therapeutics’s reported figures.

Based on the most recent quarter.

The official record: Intellia Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Intellia Therapeutics's current ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Intellia Therapeutics's current ratio?
Intellia Therapeutics (NTLA) reported current ratio of 6.1× in Q1 2026.
How has Intellia Therapeutics's current ratio changed year-over-year?
Intellia Therapeutics's current ratio increased by 24.6% year-over-year, from 4.9× to 6.1×.
What is the long-term trend for Intellia Therapeutics's current ratio?
Over 5 years (2020 to 2025), Intellia Therapeutics's current ratio has grown at a -11.9% compound annual growth rate (CAGR), from 9.6× to 5.1×.
What does current ratio mean?
Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.